Combining prostate health index and multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer in an Asian population
Objective To evaluate the practicability of combining prostate health index (PHI) and multiparametric magnetic resonance imaging (mpMRI) for the detection of clinically significant prostate cancer (csPC) in an Asian population. Patients and methods We prospectively enrolled patients who underwent pr...
Uloženo v:
| Vydáno v: | World journal of urology Ročník 38; číslo 5; s. 1207 - 1214 |
|---|---|
| Hlavní autoři: | , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.05.2020
Springer Nature B.V |
| Témata: | |
| ISSN: | 0724-4983, 1433-8726, 1433-8726 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Objective
To evaluate the practicability of combining prostate health index (PHI) and multiparametric magnetic resonance imaging (mpMRI) for the detection of clinically significant prostate cancer (csPC) in an Asian population.
Patients and methods
We prospectively enrolled patients who underwent prostate biopsy due to elevated serum prostate-specific antigen (PSA > 4 ng/mL) and/or abnormal digital rectal examination in a tertiary referral center. Before prostate biopsy, the serum samples were tested for PSA, free PSA, and p2PSA to calculate PHI. Besides, mpMRI was performed using a 3-T scanner and reported in the Prostate Imaging Reporting and Data System version 2 (PI-RADS v2). The diagnostic performance of PHI, mpMRI, and combination of both was assessed.
Result
Among 102 subjects, 39 (38.2%) were diagnosed with PC, including 24 (23.5%) with csPC (Gleason ≥ 7). By the threshold of PI-RADS ≥ 3, the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) to predict csPC were 100%, 44.9%, 35.8%, and 100%, respectively. By the threshold of PHI ≥ 30, the sensitivity, specificity, PPV, and NPV to predict csPC were 91.7%, 43.6%, 33.3%, and 94.4%, respectively. The area under the receiver operator characteristic curve of combining PHI and mpMRI was greater than that of PHI alone (0.873 vs. 0.735,
p
= 0.002) and mpMRI alone (0.873 vs. 0.830,
p
= 0.035). If biopsy was restricted to patients with PI-RADS 5 as well as PI-RADS 3 or 4 and PHI ≥ 30, 50% of biopsy could be avoided with one csPC patient being missed.
Conclusion
The combination of PHI and mpMRI had higher accuracy for detection of csPC compared with PHI or mpMRI alone in an Asian population. |
|---|---|
| AbstractList | To evaluate the practicability of combining prostate health index (PHI) and multiparametric magnetic resonance imaging (mpMRI) for the detection of clinically significant prostate cancer (csPC) in an Asian population.
We prospectively enrolled patients who underwent prostate biopsy due to elevated serum prostate-specific antigen (PSA > 4 ng/mL) and/or abnormal digital rectal examination in a tertiary referral center. Before prostate biopsy, the serum samples were tested for PSA, free PSA, and p2PSA to calculate PHI. Besides, mpMRI was performed using a 3-T scanner and reported in the Prostate Imaging Reporting and Data System version 2 (PI-RADS v2). The diagnostic performance of PHI, mpMRI, and combination of both was assessed.
Among 102 subjects, 39 (38.2%) were diagnosed with PC, including 24 (23.5%) with csPC (Gleason ≥ 7). By the threshold of PI-RADS ≥ 3, the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) to predict csPC were 100%, 44.9%, 35.8%, and 100%, respectively. By the threshold of PHI ≥ 30, the sensitivity, specificity, PPV, and NPV to predict csPC were 91.7%, 43.6%, 33.3%, and 94.4%, respectively. The area under the receiver operator characteristic curve of combining PHI and mpMRI was greater than that of PHI alone (0.873 vs. 0.735, p = 0.002) and mpMRI alone (0.873 vs. 0.830, p = 0.035). If biopsy was restricted to patients with PI-RADS 5 as well as PI-RADS 3 or 4 and PHI ≥ 30, 50% of biopsy could be avoided with one csPC patient being missed.
The combination of PHI and mpMRI had higher accuracy for detection of csPC compared with PHI or mpMRI alone in an Asian population. ObjectiveTo evaluate the practicability of combining prostate health index (PHI) and multiparametric magnetic resonance imaging (mpMRI) for the detection of clinically significant prostate cancer (csPC) in an Asian population.Patients and methodsWe prospectively enrolled patients who underwent prostate biopsy due to elevated serum prostate-specific antigen (PSA > 4 ng/mL) and/or abnormal digital rectal examination in a tertiary referral center. Before prostate biopsy, the serum samples were tested for PSA, free PSA, and p2PSA to calculate PHI. Besides, mpMRI was performed using a 3-T scanner and reported in the Prostate Imaging Reporting and Data System version 2 (PI-RADS v2). The diagnostic performance of PHI, mpMRI, and combination of both was assessed.ResultAmong 102 subjects, 39 (38.2%) were diagnosed with PC, including 24 (23.5%) with csPC (Gleason ≥ 7). By the threshold of PI-RADS ≥ 3, the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) to predict csPC were 100%, 44.9%, 35.8%, and 100%, respectively. By the threshold of PHI ≥ 30, the sensitivity, specificity, PPV, and NPV to predict csPC were 91.7%, 43.6%, 33.3%, and 94.4%, respectively. The area under the receiver operator characteristic curve of combining PHI and mpMRI was greater than that of PHI alone (0.873 vs. 0.735, p = 0.002) and mpMRI alone (0.873 vs. 0.830, p = 0.035). If biopsy was restricted to patients with PI-RADS 5 as well as PI-RADS 3 or 4 and PHI ≥ 30, 50% of biopsy could be avoided with one csPC patient being missed.ConclusionThe combination of PHI and mpMRI had higher accuracy for detection of csPC compared with PHI or mpMRI alone in an Asian population. To evaluate the practicability of combining prostate health index (PHI) and multiparametric magnetic resonance imaging (mpMRI) for the detection of clinically significant prostate cancer (csPC) in an Asian population.OBJECTIVETo evaluate the practicability of combining prostate health index (PHI) and multiparametric magnetic resonance imaging (mpMRI) for the detection of clinically significant prostate cancer (csPC) in an Asian population.We prospectively enrolled patients who underwent prostate biopsy due to elevated serum prostate-specific antigen (PSA > 4 ng/mL) and/or abnormal digital rectal examination in a tertiary referral center. Before prostate biopsy, the serum samples were tested for PSA, free PSA, and p2PSA to calculate PHI. Besides, mpMRI was performed using a 3-T scanner and reported in the Prostate Imaging Reporting and Data System version 2 (PI-RADS v2). The diagnostic performance of PHI, mpMRI, and combination of both was assessed.PATIENTS AND METHODSWe prospectively enrolled patients who underwent prostate biopsy due to elevated serum prostate-specific antigen (PSA > 4 ng/mL) and/or abnormal digital rectal examination in a tertiary referral center. Before prostate biopsy, the serum samples were tested for PSA, free PSA, and p2PSA to calculate PHI. Besides, mpMRI was performed using a 3-T scanner and reported in the Prostate Imaging Reporting and Data System version 2 (PI-RADS v2). The diagnostic performance of PHI, mpMRI, and combination of both was assessed.Among 102 subjects, 39 (38.2%) were diagnosed with PC, including 24 (23.5%) with csPC (Gleason ≥ 7). By the threshold of PI-RADS ≥ 3, the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) to predict csPC were 100%, 44.9%, 35.8%, and 100%, respectively. By the threshold of PHI ≥ 30, the sensitivity, specificity, PPV, and NPV to predict csPC were 91.7%, 43.6%, 33.3%, and 94.4%, respectively. The area under the receiver operator characteristic curve of combining PHI and mpMRI was greater than that of PHI alone (0.873 vs. 0.735, p = 0.002) and mpMRI alone (0.873 vs. 0.830, p = 0.035). If biopsy was restricted to patients with PI-RADS 5 as well as PI-RADS 3 or 4 and PHI ≥ 30, 50% of biopsy could be avoided with one csPC patient being missed.RESULTAmong 102 subjects, 39 (38.2%) were diagnosed with PC, including 24 (23.5%) with csPC (Gleason ≥ 7). By the threshold of PI-RADS ≥ 3, the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) to predict csPC were 100%, 44.9%, 35.8%, and 100%, respectively. By the threshold of PHI ≥ 30, the sensitivity, specificity, PPV, and NPV to predict csPC were 91.7%, 43.6%, 33.3%, and 94.4%, respectively. The area under the receiver operator characteristic curve of combining PHI and mpMRI was greater than that of PHI alone (0.873 vs. 0.735, p = 0.002) and mpMRI alone (0.873 vs. 0.830, p = 0.035). If biopsy was restricted to patients with PI-RADS 5 as well as PI-RADS 3 or 4 and PHI ≥ 30, 50% of biopsy could be avoided with one csPC patient being missed.The combination of PHI and mpMRI had higher accuracy for detection of csPC compared with PHI or mpMRI alone in an Asian population.CONCLUSIONThe combination of PHI and mpMRI had higher accuracy for detection of csPC compared with PHI or mpMRI alone in an Asian population. Objective To evaluate the practicability of combining prostate health index (PHI) and multiparametric magnetic resonance imaging (mpMRI) for the detection of clinically significant prostate cancer (csPC) in an Asian population. Patients and methods We prospectively enrolled patients who underwent prostate biopsy due to elevated serum prostate-specific antigen (PSA > 4 ng/mL) and/or abnormal digital rectal examination in a tertiary referral center. Before prostate biopsy, the serum samples were tested for PSA, free PSA, and p2PSA to calculate PHI. Besides, mpMRI was performed using a 3-T scanner and reported in the Prostate Imaging Reporting and Data System version 2 (PI-RADS v2). The diagnostic performance of PHI, mpMRI, and combination of both was assessed. Result Among 102 subjects, 39 (38.2%) were diagnosed with PC, including 24 (23.5%) with csPC (Gleason ≥ 7). By the threshold of PI-RADS ≥ 3, the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) to predict csPC were 100%, 44.9%, 35.8%, and 100%, respectively. By the threshold of PHI ≥ 30, the sensitivity, specificity, PPV, and NPV to predict csPC were 91.7%, 43.6%, 33.3%, and 94.4%, respectively. The area under the receiver operator characteristic curve of combining PHI and mpMRI was greater than that of PHI alone (0.873 vs. 0.735, p = 0.002) and mpMRI alone (0.873 vs. 0.830, p = 0.035). If biopsy was restricted to patients with PI-RADS 5 as well as PI-RADS 3 or 4 and PHI ≥ 30, 50% of biopsy could be avoided with one csPC patient being missed. Conclusion The combination of PHI and mpMRI had higher accuracy for detection of csPC compared with PHI or mpMRI alone in an Asian population. |
| Author | Hsieh, Po-Fan Chang, Yi-Huei Wu, Hsi-Chin Chang, Chao-Hsiang Yang, Chi-Rei Li, Wei-Juan Chen, Wen-Chi Chang, Han Huang, Chi-Ping Lin, Wei-Ching |
| Author_xml | – sequence: 1 givenname: Po-Fan surname: Hsieh fullname: Hsieh, Po-Fan organization: Department of Urology, China Medical University Hospital, School of Medicine, China Medical University, Graduate Institute of Biomedical Sciences, School of Medicine, China Medical University – sequence: 2 givenname: Wei-Juan surname: Li fullname: Li, Wei-Juan organization: Department of Urology, China Medical University Hospital – sequence: 3 givenname: Wei-Ching surname: Lin fullname: Lin, Wei-Ching organization: School of Medicine, China Medical University, Department of Radiology, China Medical University Hospital – sequence: 4 givenname: Han surname: Chang fullname: Chang, Han organization: Department of Pathology, School of Medicine, China Medical University – sequence: 5 givenname: Chao-Hsiang surname: Chang fullname: Chang, Chao-Hsiang organization: Department of Urology, China Medical University Hospital – sequence: 6 givenname: Chi-Ping surname: Huang fullname: Huang, Chi-Ping organization: Department of Urology, China Medical University Hospital, School of Medicine, China Medical University – sequence: 7 givenname: Chi-Rei surname: Yang fullname: Yang, Chi-Rei organization: Department of Urology, China Medical University Hospital – sequence: 8 givenname: Wen-Chi surname: Chen fullname: Chen, Wen-Chi organization: Department of Urology, China Medical University Hospital – sequence: 9 givenname: Yi-Huei surname: Chang fullname: Chang, Yi-Huei organization: Department of Urology, China Medical University Hospital – sequence: 10 givenname: Hsi-Chin surname: Wu fullname: Wu, Hsi-Chin email: d4746@mail.bh.cmu.edu.tw organization: Department of Urology, China Medical University Hospital, School of Medicine, China Medical University, Department of Urology, China Medical University Beigang Hospital |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31440806$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Uk1vFSEUJabGvj79Ay4MiZtuRoHhY9iYNC9WTZq40TXhMcw8GgZGYIz9N_5Umb7Wahdd8HU559zD5Z6BkxCDBeA1Ru8wQuJ9RqilrEFYNoh0nWzIM7DBtG2bThB-AjZIENpQ2bWn4Czna4Sw4Ii9AKctphR1iG_A712c9i64MMI5xVx0sfBgtS8H6EJvf0EdejgtvrhZJz3ZkpyBkx6DLXWTbI5BB2Ohq7FVxAVYDhb2rkJidhnGARpfExjt_Q3MbgxuqIdQHvKZVSGtVB3gRXZ1nuO8eF1cDC_B80H7bF_drVvw_fLjt93n5urrpy-7i6vGMIpKYzqJOTZM0g53GkuGOKcWYUJ4jxmSdXDGBdJamBqiDA_CML7XZDBcDrbdgg9H3XnZT7Y3NpSkvZpTfVm6UVE79f9NcAc1xp9KYIlYh6vA-Z1Aij8Wm4uaXDbWex1sXLIibctlhXJZoW8fQa_jkkJ9niJECMHa9dO24M2_jv5auf-8CuiOAFMrmZMdlHHltmjVoPMKI7X2iTr2iap9om77pFrZAvKIeq_-JKk9knIFh9GmB9tPsP4ACGnS6g |
| CitedBy_id | crossref_primary_10_3389_fonc_2022_1068893 crossref_primary_10_1515_cclm_2019_0693 crossref_primary_10_1007_s00345_020_03585_2 crossref_primary_10_1097_JCMA_0000000000001117 crossref_primary_10_1001_jamanetworkopen_2024_4258 crossref_primary_10_1016_j_compbiomed_2025_110440 crossref_primary_10_1515_cclm_2022_0354 crossref_primary_10_1002_pros_70025 crossref_primary_10_3390_life13030638 crossref_primary_10_1177_17562872221103988 crossref_primary_10_1016_j_euo_2023_10_029 crossref_primary_10_3390_cancers14174174 crossref_primary_10_3390_cancers13184723 crossref_primary_10_1259_bjr_20191050 crossref_primary_10_1016_j_bulcan_2021_11_010 crossref_primary_10_3390_cancers13133373 crossref_primary_10_1016_j_clgc_2022_04_013 crossref_primary_10_1097_JCMA_0000000000000845 crossref_primary_10_1002_ijc_33045 crossref_primary_10_3390_jcm12010339 crossref_primary_10_3233_CBM_201600 crossref_primary_10_1097_JU_0000000000002958 crossref_primary_10_1007_s11255_022_03113_8 crossref_primary_10_1002_pros_70055 crossref_primary_10_1007_s00345_025_05820_0 crossref_primary_10_1016_S1470_2045_21_00348_X crossref_primary_10_3390_cancers13235932 crossref_primary_10_1016_j_euros_2022_10_017 crossref_primary_10_4103_UROS_UROS_33_22 crossref_primary_10_1038_s41598_020_78428_6 crossref_primary_10_1097_RLU_0000000000004228 crossref_primary_10_1097_JU_0000000000003450 crossref_primary_10_1111_iju_70024 crossref_primary_10_1007_s00345_022_04272_0 crossref_primary_10_3389_fonc_2022_911725 crossref_primary_10_3389_fonc_2021_772182 crossref_primary_10_3389_fsurg_2024_1429831 crossref_primary_10_1186_s12894_021_00928_y crossref_primary_10_3390_ijms21041184 crossref_primary_10_1177_15330338241290029 crossref_primary_10_1016_j_urolonc_2024_02_009 crossref_primary_10_3390_diagnostics13213350 crossref_primary_10_1007_s00345_023_04613_7 |
| Cites_doi | 10.1111/iju.13593 10.2307/2531595 10.1373/clinchem.2012.195784 10.1016/j.juro.2014.10.121 10.1007/s00345-012-0927-9 10.1016/j.clinbiochem.2010.04.062 10.1016/S0022-5347(17)35233-3 10.1016/j.eururo.2015.01.013 10.1016/j.eururo.2015.08.052 10.1016/j.eururo.2017.02.021 10.1016/S0140-6736(16)32401-1 10.1016/j.eururo.2014.11.037 10.1016/j.eururo.2010.02.003 10.1111/bju.13676 10.1038/pcan.2016.72 10.1002/pros.23382 10.1016/j.juro.2015.01.091 10.1016/j.eururo.2011.02.034 10.1111/bju.14098 10.3322/caac.21387 10.1080/21681805.2017.1298155 10.1016/j.eururo.2013.10.048 10.4103/1008-682X.168687 10.1016/j.juro.2016.06.079 10.1038/srep35364 10.1016/j.eururo.2013.03.030 10.1016/j.eururo.2018.10.047 10.1056/NEJMoa1801993 10.1016/j.eururo.2017.01.042 10.1038/pcan.2017.3 10.1097/PAS.0000000000000530 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2019 The Author(s) 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2019 – notice: The Author(s) 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T5 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM |
| DOI | 10.1007/s00345-019-02889-2 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE ProQuest One Academic Middle East (New) MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1433-8726 |
| EndPage | 1214 |
| ExternalDocumentID | PMC7190581 31440806 10_1007_s00345_019_02889_2 |
| Genre | Journal Article |
| GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 123 1N0 1SB 2.D 203 28- 29R 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3O- 3V. 4.4 406 408 409 40D 40E 53G 5QI 5RE 5VS 67Z 6NX 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACUDM ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BSONS BVXVI C6C CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M4Y MA- N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WH7 WJK WK8 YLTOR Z45 Z7U Z7X Z82 Z83 Z87 Z8O Z8V Z8W Z91 ZGI ZMTXR ZOVNA ~EX ~KM AAPKM AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC ADHKG AEZWR AFDZB AFFHD AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY CGR CUY CVF ECM EIF NPM 7T5 7XB 8FK H94 K9. PKEHL PQEST PQUKI 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c540t-c89161c594818a1950664e01226d150915065670aa7c26d451f7c56ba2fc69fe3 |
| IEDL.DBID | BENPR |
| ISICitedReferencesCount | 50 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000529536600015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0724-4983 1433-8726 |
| IngestDate | Tue Nov 04 01:54:35 EST 2025 Thu Sep 04 19:07:32 EDT 2025 Tue Nov 04 22:18:14 EST 2025 Mon Jul 21 05:40:19 EDT 2025 Sat Nov 29 02:58:29 EST 2025 Tue Nov 18 22:20:07 EST 2025 Fri Feb 21 02:34:34 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | Prostate health index Prostate cancer detection mpMRI PI-RADS |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c540t-c89161c594818a1950664e01226d150915065670aa7c26d451f7c56ba2fc69fe3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://link.springer.com/10.1007/s00345-019-02889-2 |
| PMID | 31440806 |
| PQID | 2277753498 |
| PQPubID | 36817 |
| PageCount | 8 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7190581 proquest_miscellaneous_2336990569 proquest_journals_2277753498 pubmed_primary_31440806 crossref_citationtrail_10_1007_s00345_019_02889_2 crossref_primary_10_1007_s00345_019_02889_2 springer_journals_10_1007_s00345_019_02889_2 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-05-01 |
| PublicationDateYYYYMMDD | 2020-05-01 |
| PublicationDate_xml | – month: 05 year: 2020 text: 2020-05-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Berlin/Heidelberg |
| PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Berlin |
| PublicationTitle | World journal of urology |
| PublicationTitleAbbrev | World J Urol |
| PublicationTitleAlternate | World J Urol |
| PublicationYear | 2020 |
| Publisher | Springer Berlin Heidelberg Springer Nature B.V |
| Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer Nature B.V |
| References | De La Calle, Patil, Wei, Scherr, Sokoll, Chan, Siddiqui, Mosquera, Rubin, Sanda (CR6) 2015; 194 Druskin, Tosoian, Young, Collica, Srivastava, Ghabili, Macura, Carter, Partin, Sokoll, Ross, Pavlovich (CR32) 2018; 121 Stephan, Vincendeau, Houlgatte, Cammann, Jung, Semjonow (CR4) 2013; 59 Moore, Kasivisvanathan, Eggener, Emberton, Fütterer, Gill, Grubb Iii, Hadaschik, Klotz, Margolis, Marks, Melamed, Oto, Palmer, Pinto, Puech, Punwani, Rosenkrantz, Schoots, Simon, Taneja, Turkbey, Ukimura, van der Meulen, Villers, Watanabe (CR16) 2013; 64 Siegel, Miller, Jemal (CR1) 2017; 67 Kimura, Egawa (CR2) 2018; 25 Fütterer, Briganti, De Visschere, Emberton, Giannarini, Kirkham, Taneja, Thoeny, Villeirs, Villers (CR23) 2015; 68 Ahmed, El-Shater Bosaily, Brown, Gabe, Kaplan, Parmar, Collaco-Moraes, Ward, Hindley, Freeman, Kirkham, Oldroyd, Parker, Emberton (CR12) 2017; 389 Loeb, Shin, Broyles, Wei, Sanda, Klee, Partin, Sokoll, Chan, Bangma, van Schaik, Slawin, Marks, Catalona (CR24) 2017; 120 Kasivisvanathan, Rannikko, Borghi, Panebianco, Mynderse, Vaarala, Briganti, Budäus, Hellawell, Hindley (CR8) 2018; 378 Furuya, Kawahara, Narahara, Tokita, Fukui, Imano, Mitome, Ito, Izumi, Osaka (CR15) 2017; 51 Tan, Tan, Tai, Tan, Gauhar, Tiong, Hawkins, Thamboo, Hong, Chiong (CR27) 2017; 19 Gnanapragasam, Burling, George, Stearn, Warren, Barrett, Koo, Gallagher, Doble, Kastner, Parker (CR13) 2016; 6 CR31 Na, Ye, Qi, Liu, Helfand, Brendler, Conran, Packiam, Gong, Wu, Zheng, Mo, Ding, Sun, Xu (CR28) 2017; 77 Schoots, Roobol, Nieboer, Bangma, Steyerberg, Hunink (CR9) 2015; 68 Semjonow, Köpke, Eltze, Pepping-Schefers, Bürgel, Darte (CR17) 2010; 43 Loeb, Sanda, Broyles, Shin, Bangma, Wei, Partin, Klee, Slawin, Marks (CR5) 2015; 193 Jansen, van Schaik, Kurstjens, Horninger, Klocker, Bektic, Wildhagen, Roobol, Bangma, Bartsch (CR18) 2010; 57 DeLong, DeLong, Clarke-Pearson (CR22) 1988; 44 Sciarra, Barentsz, Bjartell, Eastham, Hricak, Panebianco, Witjes (CR7) 2011; 59 Chiu, Ng, Semjonow, Zhu, Vincendeau, Houlgatte, Lazzeri, Guazzoni, Stephan, Haese, Bruijne, Teoh, Leung, Casale, Chiang, Tan, Chiong, Huang, Wu, Nieboer, Ye, Bangma, Roobol (CR21) 2019; 75 Catalona, Richie, Ahmann, M’Liss, Scardino, Flanigan, Dekernion, Ratliff, Kavoussi, Dalkin (CR3) 1994; 151 Epstein, Egevad, Amin, Delahunt, Srigley, Humphrey (CR19) 2016; 40 Rosenkrantz, Verma, Choyke, Eberhardt, Eggener, Gaitonde, Haider, Margolis, Marks, Pinto, Sonn, Taneja (CR29) 2016; 196 CR25 Venderink, van Luijtelaar, Bomers, van der Leest, Hulsbergen-van de Kaa, Barentsz, Sedelaar, Fütterer (CR30) 2018; 73 Wysock, Rosenkrantz, Huang, Stifelman, Lepor, Deng, Melamed, Taneja (CR20) 2014; 66 Weinreb, Barentsz, Choyke, Cornud, Haider, Macura, Margolis, Schnall, Shtern, Tempany (CR10) 2016; 69 Ito, Miyakubo, Sekine, Koike, Matsui, Shibata, Suzuki (CR26) 2013; 31 Woo, Suh, Kim, Cho, Kim (CR11) 2017; 72 Tosoian, Druskin, Andreas, Mullane, Chappidi, Joo, Ghabili, Mamawala, Agostino, Carter, Partin, Sokoll, Ross (CR14) 2017; 20 FH Jansen (2889_CR18) 2010; 57 K Furuya (2889_CR15) 2017; 51 JS Wysock (2889_CR20) 2014; 66 R Na (2889_CR28) 2017; 77 S Loeb (2889_CR24) 2017; 120 IG Schoots (2889_CR9) 2015; 68 A Sciarra (2889_CR7) 2011; 59 HU Ahmed (2889_CR12) 2017; 389 K Ito (2889_CR26) 2013; 31 S Woo (2889_CR11) 2017; 72 W Venderink (2889_CR30) 2018; 73 2889_CR31 JC Weinreb (2889_CR10) 2016; 69 JI Epstein (2889_CR19) 2016; 40 T Kimura (2889_CR2) 2018; 25 S Loeb (2889_CR5) 2015; 193 C De La Calle (2889_CR6) 2015; 194 WJ Catalona (2889_CR3) 1994; 151 C Stephan (2889_CR4) 2013; 59 LG Tan (2889_CR27) 2017; 19 RL Siegel (2889_CR1) 2017; 67 2889_CR25 A Semjonow (2889_CR17) 2010; 43 ER DeLong (2889_CR22) 1988; 44 V Kasivisvanathan (2889_CR8) 2018; 378 CM Moore (2889_CR16) 2013; 64 VJ Gnanapragasam (2889_CR13) 2016; 6 PK Chiu (2889_CR21) 2019; 75 JJ Fütterer (2889_CR23) 2015; 68 JJ Tosoian (2889_CR14) 2017; 20 AB Rosenkrantz (2889_CR29) 2016; 196 SC Druskin (2889_CR32) 2018; 121 |
| References_xml | – volume: 25 start-page: 524 issue: 6 year: 2018 end-page: 531 ident: CR2 article-title: Epidemiology of prostate cancer in Asian countries publication-title: Int J Urol doi: 10.1111/iju.13593 – volume: 44 start-page: 837 issue: 3 year: 1988 end-page: 845 ident: CR22 article-title: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach publication-title: Biometrics doi: 10.2307/2531595 – volume: 59 start-page: 306 issue: 1 year: 2013 end-page: 314 ident: CR4 article-title: Multicenter evaluation of [− 2] proprostate-specific antigen and the prostate health index for detecting prostate cancer publication-title: Clin Chem doi: 10.1373/clinchem.2012.195784 – volume: 193 start-page: 1163 issue: 4 year: 2015 end-page: 1169 ident: CR5 article-title: The prostate health index selectively identifies clinically significant prostate cancer publication-title: J Urol doi: 10.1016/j.juro.2014.10.121 – volume: 31 start-page: 305 issue: 2 year: 2013 end-page: 311 ident: CR26 article-title: Diagnostic significance of [– 2] pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0–10.0 ng/mL range publication-title: World J Urol doi: 10.1007/s00345-012-0927-9 – volume: 43 start-page: 926 issue: 10–11 year: 2010 end-page: 928 ident: CR17 article-title: Pre-analytical in-vitro stability of [− 2] proPSA in blood and serum publication-title: Clin Biochem doi: 10.1016/j.clinbiochem.2010.04.062 – volume: 151 start-page: 1283 issue: 5 year: 1994 end-page: 1290 ident: CR3 article-title: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men publication-title: J Urol doi: 10.1016/S0022-5347(17)35233-3 – volume: 68 start-page: 1045 issue: 6 year: 2015 end-page: 1053 ident: CR23 article-title: Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature publication-title: Eur Urol doi: 10.1016/j.eururo.2015.01.013 – volume: 69 start-page: 16 issue: 1 year: 2016 end-page: 40 ident: CR10 article-title: PI-RADS prostate imaging–reporting and data system: 2015, version 2 publication-title: Eur Urol doi: 10.1016/j.eururo.2015.08.052 – volume: 73 start-page: 353 issue: 3 year: 2018 end-page: 360 ident: CR30 article-title: Results of targeted biopsy in men with magnetic resonance imaging lesions classified equivocal, likely or highly likely to be clinically significant prostate cancer publication-title: Eur Urol doi: 10.1016/j.eururo.2017.02.021 – ident: CR25 – volume: 389 start-page: 815 issue: 10071 year: 2017 end-page: 822 ident: CR12 article-title: Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study publication-title: Lancet doi: 10.1016/S0140-6736(16)32401-1 – volume: 68 start-page: 438 issue: 3 year: 2015 end-page: 450 ident: CR9 article-title: Magnetic resonance imaging–targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis publication-title: Eur Urol doi: 10.1016/j.eururo.2014.11.037 – volume: 57 start-page: 921 issue: 6 year: 2010 end-page: 927 ident: CR18 article-title: Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection publication-title: Eur Urol doi: 10.1016/j.eururo.2010.02.003 – volume: 120 start-page: 61 issue: 1 year: 2017 end-page: 68 ident: CR24 article-title: Prostate health index improves multivariable risk prediction of aggressive prostate cancer publication-title: BJU Int doi: 10.1111/bju.13676 – volume: 20 start-page: 228 issue: 2 year: 2017 end-page: 233 ident: CR14 article-title: Use of the prostate health index for detection of prostate cancer: results from a large academic practice publication-title: Prostate Cancer Prostatic Dis doi: 10.1038/pcan.2016.72 – volume: 77 start-page: 1221 issue: 11 year: 2017 end-page: 1229 ident: CR28 article-title: Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2–10 ng/mL and PSA > 10 ng/mL: results from a Multicenter Study in China publication-title: Prostate doi: 10.1002/pros.23382 – volume: 194 start-page: 65 issue: 1 year: 2015 end-page: 72 ident: CR6 article-title: Multicenter evaluation of the prostate health index to detect aggressive prostate cancer in biopsy naive men publication-title: J Urol doi: 10.1016/j.juro.2015.01.091 – volume: 59 start-page: 962 issue: 6 year: 2011 end-page: 977 ident: CR7 article-title: Advances in magnetic resonance imaging: how they are changing the management of prostate cancer publication-title: Eur Urol doi: 10.1016/j.eururo.2011.02.034 – volume: 121 start-page: 619 issue: 4 year: 2018 end-page: 626 ident: CR32 article-title: Combining prostate health index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer publication-title: BJU Int doi: 10.1111/bju.14098 – volume: 67 start-page: 7 issue: 1 year: 2017 end-page: 30 ident: CR1 article-title: Cancer statistics publication-title: CA Cancer J Clin doi: 10.3322/caac.21387 – volume: 51 start-page: 251 issue: 4 year: 2017 end-page: 257 ident: CR15 article-title: Measurement of serum isoform [– 2] proPSA derivatives shows superior accuracy to magnetic resonance imaging in the diagnosis of prostate cancer in patients with a total prostate-specific antigen level of 2–10 ng/ml publication-title: Scand J Urol doi: 10.1080/21681805.2017.1298155 – volume: 66 start-page: 343 issue: 2 year: 2014 end-page: 351 ident: CR20 article-title: A prospective, blinded comparison of magnetic resonance (MR) imaging–ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: the PROFUS trial publication-title: Eur Urol doi: 10.1016/j.eururo.2013.10.048 – ident: CR31 – volume: 19 start-page: 286 issue: 3 year: 2017 end-page: 290 ident: CR27 article-title: Prospective validation of %p2PSA and the prostate health index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4–10 ng ml publication-title: Asian J Androl doi: 10.4103/1008-682X.168687 – volume: 196 start-page: 1613 issue: 6 year: 2016 end-page: 1618 ident: CR29 article-title: Prostate magnetic resonance imaging and magnetic resonance imaging targeted biopsy in patients with a prior negative biopsy: a consensus statement by AUA and SAR publication-title: J Urol doi: 10.1016/j.juro.2016.06.079 – volume: 40 start-page: 244 issue: 2 year: 2016 end-page: 252 ident: CR19 article-title: The 2014 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma publication-title: Am J Surg Pathol – volume: 6 start-page: 35364 year: 2016 ident: CR13 article-title: The prostate health index adds predictive value to multi-parametric MRI in detecting significant prostate cancers in a repeat biopsy population publication-title: Sci Rep doi: 10.1038/srep35364 – volume: 64 start-page: 544 issue: 4 year: 2013 end-page: 552 ident: CR16 article-title: Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an international working group publication-title: Eur Urol doi: 10.1016/j.eururo.2013.03.030 – volume: 75 start-page: 558 issue: 4 year: 2019 end-page: 561 ident: CR21 article-title: A multicentre evaluation of the role of the prostate health index (PHI) in regions with differing prevalence of prostate cancer: adjustment of PHI reference ranges is needed for European and Asian settings publication-title: Eur Urol doi: 10.1016/j.eururo.2018.10.047 – volume: 378 start-page: 1767 issue: 19 year: 2018 end-page: 1777 ident: CR8 article-title: MRI-targeted or standard biopsy for prostate-cancer diagnosis publication-title: N Engl J Med doi: 10.1056/NEJMoa1801993 – volume: 72 start-page: 177 issue: 2 year: 2017 end-page: 188 ident: CR11 article-title: Diagnostic performance of prostate imaging reporting and data system version 2 for detection of prostate cancer: a systematic review and diagnostic meta-analysis publication-title: Eur Urol doi: 10.1016/j.eururo.2017.01.042 – volume: 73 start-page: 353 issue: 3 year: 2018 ident: 2889_CR30 publication-title: Eur Urol doi: 10.1016/j.eururo.2017.02.021 – ident: 2889_CR31 doi: 10.1038/pcan.2017.3 – volume: 67 start-page: 7 issue: 1 year: 2017 ident: 2889_CR1 publication-title: CA Cancer J Clin doi: 10.3322/caac.21387 – volume: 40 start-page: 244 issue: 2 year: 2016 ident: 2889_CR19 publication-title: Am J Surg Pathol doi: 10.1097/PAS.0000000000000530 – volume: 196 start-page: 1613 issue: 6 year: 2016 ident: 2889_CR29 publication-title: J Urol doi: 10.1016/j.juro.2016.06.079 – volume: 6 start-page: 35364 year: 2016 ident: 2889_CR13 publication-title: Sci Rep doi: 10.1038/srep35364 – volume: 44 start-page: 837 issue: 3 year: 1988 ident: 2889_CR22 publication-title: Biometrics doi: 10.2307/2531595 – volume: 151 start-page: 1283 issue: 5 year: 1994 ident: 2889_CR3 publication-title: J Urol doi: 10.1016/S0022-5347(17)35233-3 – volume: 57 start-page: 921 issue: 6 year: 2010 ident: 2889_CR18 publication-title: Eur Urol doi: 10.1016/j.eururo.2010.02.003 – volume: 66 start-page: 343 issue: 2 year: 2014 ident: 2889_CR20 publication-title: Eur Urol doi: 10.1016/j.eururo.2013.10.048 – volume: 120 start-page: 61 issue: 1 year: 2017 ident: 2889_CR24 publication-title: BJU Int doi: 10.1111/bju.13676 – volume: 19 start-page: 286 issue: 3 year: 2017 ident: 2889_CR27 publication-title: Asian J Androl doi: 10.4103/1008-682X.168687 – volume: 75 start-page: 558 issue: 4 year: 2019 ident: 2889_CR21 publication-title: Eur Urol doi: 10.1016/j.eururo.2018.10.047 – volume: 389 start-page: 815 issue: 10071 year: 2017 ident: 2889_CR12 publication-title: Lancet doi: 10.1016/S0140-6736(16)32401-1 – volume: 77 start-page: 1221 issue: 11 year: 2017 ident: 2889_CR28 publication-title: Prostate doi: 10.1002/pros.23382 – volume: 25 start-page: 524 issue: 6 year: 2018 ident: 2889_CR2 publication-title: Int J Urol doi: 10.1111/iju.13593 – volume: 121 start-page: 619 issue: 4 year: 2018 ident: 2889_CR32 publication-title: BJU Int doi: 10.1111/bju.14098 – volume: 193 start-page: 1163 issue: 4 year: 2015 ident: 2889_CR5 publication-title: J Urol doi: 10.1016/j.juro.2014.10.121 – volume: 378 start-page: 1767 issue: 19 year: 2018 ident: 2889_CR8 publication-title: N Engl J Med doi: 10.1056/NEJMoa1801993 – volume: 194 start-page: 65 issue: 1 year: 2015 ident: 2889_CR6 publication-title: J Urol doi: 10.1016/j.juro.2015.01.091 – volume: 68 start-page: 1045 issue: 6 year: 2015 ident: 2889_CR23 publication-title: Eur Urol doi: 10.1016/j.eururo.2015.01.013 – volume: 59 start-page: 962 issue: 6 year: 2011 ident: 2889_CR7 publication-title: Eur Urol doi: 10.1016/j.eururo.2011.02.034 – volume: 20 start-page: 228 issue: 2 year: 2017 ident: 2889_CR14 publication-title: Prostate Cancer Prostatic Dis doi: 10.1038/pcan.2016.72 – volume: 43 start-page: 926 issue: 10–11 year: 2010 ident: 2889_CR17 publication-title: Clin Biochem doi: 10.1016/j.clinbiochem.2010.04.062 – ident: 2889_CR25 – volume: 59 start-page: 306 issue: 1 year: 2013 ident: 2889_CR4 publication-title: Clin Chem doi: 10.1373/clinchem.2012.195784 – volume: 31 start-page: 305 issue: 2 year: 2013 ident: 2889_CR26 publication-title: World J Urol doi: 10.1007/s00345-012-0927-9 – volume: 68 start-page: 438 issue: 3 year: 2015 ident: 2889_CR9 publication-title: Eur Urol doi: 10.1016/j.eururo.2014.11.037 – volume: 72 start-page: 177 issue: 2 year: 2017 ident: 2889_CR11 publication-title: Eur Urol doi: 10.1016/j.eururo.2017.01.042 – volume: 69 start-page: 16 issue: 1 year: 2016 ident: 2889_CR10 publication-title: Eur Urol doi: 10.1016/j.eururo.2015.08.052 – volume: 51 start-page: 251 issue: 4 year: 2017 ident: 2889_CR15 publication-title: Scand J Urol doi: 10.1080/21681805.2017.1298155 – volume: 64 start-page: 544 issue: 4 year: 2013 ident: 2889_CR16 publication-title: Eur Urol doi: 10.1016/j.eururo.2013.03.030 |
| SSID | ssj0017605 |
| Score | 2.4671824 |
| Snippet | Objective
To evaluate the practicability of combining prostate health index (PHI) and multiparametric magnetic resonance imaging (mpMRI) for the detection of... To evaluate the practicability of combining prostate health index (PHI) and multiparametric magnetic resonance imaging (mpMRI) for the detection of clinically... ObjectiveTo evaluate the practicability of combining prostate health index (PHI) and multiparametric magnetic resonance imaging (mpMRI) for the detection of... |
| SourceID | pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1207 |
| SubjectTerms | Aged Asian Continental Ancestry Group Biopsy Clinical significance Feasibility Studies Humans Kallikreins - blood Magnetic resonance imaging Male Medicine Medicine & Public Health Middle Aged Multiparametric Magnetic Resonance Imaging Nephrology NMR Nuclear magnetic resonance Oncology Original Original Article Predictive Value of Tests Prospective Studies Prostate - diagnostic imaging Prostate cancer Prostate-specific antigen Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Prostatic Neoplasms - diagnosis Prostatic Neoplasms - diagnostic imaging Rectum Sensitivity and Specificity Urology |
| SummonAdditionalLinks | – databaseName: Springer LINK dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB5RqCoupU8IpWgq9dZG2tiJnRwRKuLQItQH4hZ5J067EmRXuwtS_01_amecB1ooldprYiexM86M833zDcDbxDundU2xNxlvUMhWcWG1YPCKsspkzgbZxbOP9uQkPz8vTruksEXPdu8hyfClHpLdREpFiGZFzD5RuDkPYIPdXS7L8fOXswE7sF02pFVpnBa57lJl_nyNVXd0J8a8S5W8hZcGN3S09X8DeAKPu7ATD1o7eQprvnkGjz51wPpz-MXfhXGoFYEzyQPhCBTbFEkMeoromgpb8qETOpfo-uOl-95IDiTyln0qwh0eJ5eh6hF3Qo4ssWqJfJMFTmvskzAvfqKwRoSjxK_15n4kV5hLV9fggSR34mwoL_YCvh19-Hp4HHfFG2LiIHAZU86BZ0JBDSZ3UmzWmNQLkGeqRKIUPpAZO3LOEh9Ks6S2lJmxUzWZovb6Jaw308bvACZJZWlUkCPez1Wqcqkaj7QgmjnRuLARJP07LKlTNpcCGxfloMkcpr7kqS_D1JcqgndDn1mr6_HX1nu9aZTdGl-USlnLmz02sQjeDKd5dQrk4ho_veI2Whv295kpIthuLWm4nRZcPR-ZCOyKjQ0NRPl79Uwz-REUwC2HcVmeRPC-t7Sbx7p_FLv_1vwVbCr5uRDYnXuwvpxf-dfwkK6Xk8V8P6y533d5KDc priority: 102 providerName: Springer Nature |
| Title | Combining prostate health index and multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer in an Asian population |
| URI | https://link.springer.com/article/10.1007/s00345-019-02889-2 https://www.ncbi.nlm.nih.gov/pubmed/31440806 https://www.proquest.com/docview/2277753498 https://www.proquest.com/docview/2336990569 https://pubmed.ncbi.nlm.nih.gov/PMC7190581 |
| Volume | 38 |
| WOSCitedRecordID | wos000529536600015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAVX databaseName: SpringerLink Contemporary customDbUrl: eissn: 1433-8726 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017605 issn: 0724-4983 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Nb9QwEB3RLUJc-P4IlMpI3CBiYyd2ckIFteIAq6pAtbfIO3HKSm2y7G6R-Df8VGYcJ6ulohcukTaxk7U8tp89b94AvEqctUrVGDud0QYFTRUXRrEPXmJW6cwaL7t4-slMJvl0WhyHA7dVoFX2c6KfqKsW-Yz8rZTGELROi_zd4kfMWaPYuxpSaOzALiuVpSPYfX84OT4Z_AgmREYamcZUVYWwGR88x9IsTFwrYlpjmeuzvTRdwZtXaZN_-U79knR0938bcw_uBDAqDjrruQ83XPMAbn0O7vaH8Jtmi5nPICEWHB1CuFR0gZPCqywK21SioyRaJnmx2r-4sGcNR0YK2si3LOfhxPzC50KiSoLwpqg6et98Jdpa9KGZ578Ec0mYuUSdvfke8huWXNU24oBDPsViSDr2CL4dHX798DEOKR1iJGi4jjEnOJqg14jJLaeg1Tp17N7TVcLYhW5k2oytNUi30iypDWZ6ZmWNuqidegyjpm3cUxBJUhkcF2iRdnmVrGwqZ2PFfs4ccVaYCJK-N0sMeuecduO8HJSavQWUZAGlt4BSRvB6qLPo1D6uLb3X924ZRv6q3HRtBC-HxzRm2RFjG9deUhmlNKGATBcRPOlsavicYm97PtYRmC1rGwqwHvj2k2b-3euCGwJ3WZ5E8Ka3y83f-ncrnl3fiudwW_IRg-d47sFovbx0L-Am_lzPV8t92DFT46_5fhh79Ovky-kf1Hg2hQ |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgigX3oVAASPBCSLWdmInB4QqoGrV7YpDQXtLvbYDK7XZZXcL6r_hF_AbmXEeq6Witx64Jnae34xnPN_MALzg3hgpSxt7laKDYrWLcy0pBi9s6lRqdCi7-KWvB4NsOMw_rcHvNheGaJWtTgyK2k0s7ZG_EUJrNK2TPHs3_R5T1yiKrrYtNGpY7Puzn-iyzd_ufcD_-1KInY-H73fjpqtAbNE6WcQ2Q4uI21CmJDPUBVWpxFOESTlOyyceSJXuGaMtHkpSXmqbqpERpVV56SVe9wpcRT2uiUKmh52Dx3WTh6lFEuODyiZJJ6TqUSEYosnlMa7oxCxaXQjPWbfnSZp_RWrDArhz63_7dLfhZmNqs-1aNu7Amq_uwvWDhkxwD36hLhyF_hhsSrkvaHWzOi2UhRqSzFSO1YRLQxQ26mXATszXivI-2cyTE4Miw8YnodMTTmJoTTNXkxfHczYpWZt4enzGiClDvCyE8vJ-lq4wo6mmYtuU0MqmXUu1-_D5Ur7PJqxXk8o_BMa507aXW2PRh3XCmUSMepKiuJm1o1xHwFv0FLap5k5NRY6Lrg51QFyBiCsC4goRwatuzrSuZXLh6K0WTUWj1-bFEkoRPO9Oo0aiMJOp_OQUx0ip0MZJVR7BgxrD3e0kcQmynopAr6C7G0DVzlfPVONvoeq5RtM1zXgEr1s5WD7Wv9_i0cVv8Qw2dg8P-kV_b7D_GG4I2kwJbNYtWF_MTv0TuGZ_LMbz2dMg6QyOLls-_gC9rIrq |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Nb9QwEB2VLaq4tHwTKGAkOEHUjRPbyQGhQruialmtEKDeUq_jwEptdru7BfXf9Hfw65hxnKyWit564JrY-XxjP3vezAC8jKzWcVya0EqBCxSjijBTMfnguRGFFFq5tIvfDlS_nx4eZoMV-N3EwpCsshkT3UBdjA3tkW9xrhRS6yRLt0ovixjs9N5NTkOqIEWe1qacRg2RfXv-C5dvs7d7O_ivX3He2_3y4WPoKwyEBpnKPDQpsqPIuJQlqaaKqFImlrxNsohoKsUDQqqu1srgoUREpTJCDjUvjcxKG-N1b8CqQpIhOrD6frc_-Nz6MJSPylQ8CfGxYx-y4wL3KC0MieayEOd30hktT4uXuO5lyeZffls3HfY2_ucPeRvWPQln27XV3IEVW92FtU9eZnAPLnCUHLrKGWxCUTHIx1kdMMpcdkmmq4LVUkxN4jaqcsBO9PeKIkLZ1NLyBo2JjU5cDSjsxJBns6KWNY5mbFyyJiT1-JyRhoYUWwjyxf0MXWFKXXXFtinUlU3aYmv34eu1fJ8H0KnGlX0ELIoKZbqZ0QZXtwUvdMKH3Zj8u6kxw0wFEDVIyo3P807lRo7zNkO1Q1-O6Msd-nIewOu2z6TOcnJl680GWbkf8Wb5AlYBvGhP41hFDihd2fEZtoljiexHyCyAhzWe29vFpDJIuzIAtYT0tgHlQV8-U41-uHzoCkmtSKMA3jQ2sXisf7_F46vf4jmsoVnkB3v9_Sdwi9Mui5O5bkJnPj2zT-Gm-TkfzabPvNkzOLpuA_kDnvmVCg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Combining+prostate+health+index+and+multiparametric+magnetic+resonance+imaging+in+the+diagnosis+of+clinically+significant+prostate+cancer+in+an+Asian+population&rft.jtitle=World+journal+of+urology&rft.au=Hsieh%2C+Po-Fan&rft.au=Li%2C+Wei-Juan&rft.au=Lin%2C+Wei-Ching&rft.au=Chang%2C+Han&rft.date=2020-05-01&rft.eissn=1433-8726&rft.volume=38&rft.issue=5&rft.spage=1207&rft_id=info:doi/10.1007%2Fs00345-019-02889-2&rft_id=info%3Apmid%2F31440806&rft.externalDocID=31440806 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0724-4983&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0724-4983&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0724-4983&client=summon |